A spectacular tumor response of a giant axillary mass treated with SABR in a palliative scenario

ABSTRACT

A 67-year-old male patient with a massive left axillary metastasis from an occult primary tumor (OPT) treated by stereotactic ablative radiotherapy (SABR) is presented. The patient had no clinical response to the initial chemotherapy treatment. Then, a SABR with a single fraction of 16Gy was performed. After SABR, a complete response was observed in the imaging exams after 3 months from the procedure. Currently, the patient is found with painfree, without any analgesic drug. The present case illustrates the importance of considering SABR in palliate care, even for a large tumor.

RESUMO

Apresentamos um paciente do sexo masculino de 67 anos com uma metástase axilar esquerda maciça de um tumor primário oculto (TPO) que foi tratado com radioterapia estereotáxica ablativa (REA). O paciente não apresentou resposta clínica ao tratamento quimioterápico inicial. Em seguida, foi realizado uma REA com uma única fração de 16Gy. Após a REA, foi observada resposta completa nos exames de imagem após 3 meses do procedimento. Atualmente, o paciente encontra-se sem dor, sem nenhum analgésico. O presente caso ilustra a importância de considerar a REA no cuidado paliativo, mesmo para um tumor grande.

Keywords:

Radiotherapy - Cancer - SABR - Oligometastasis.

Descritores:

Radioterapia - Câncer - REA - Oligometástases.

Authors' contributions

All authors participated the study design, data extraction, and analysis.

Financial support: none to declare.

FUNDING SOURCE

None.

COMPETING INTERESTS

The authors declare that they have no competing interests.

Publication History

Received: 14 June 2021

Accepted: 25 June 2021

Article published online:
15 July 2021

• REFERENCES

• Qaseem A, Usman N, Jayaraj JS, Janapala RN, Kashif T.. Cancer of unknown primary: a review on clinical guidelines in the development and targeted management of patients with the unknown primary site. Cureus [Internet] 2020; [Sep cited 2020 Jul 8]; 11 (09) e5552 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820325
• Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N. et al Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000; Sep; 18 (17) 3101-3107
• Greco FA, Rodriguez GI, Shaffer DW, Hermann R, Litchy S, Yardley DA. et al Carcinoma of unknown primary site: sequential treatment with paclitaxel/ carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist 2004; Nov; 9 (06) 644-652 https://doi.org/10.1634/theoncologist.9-6-644
• Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C. et al Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019; May; 393 (10185): 2051-2058
• Timmerman RD, Herman J, Cho LC.. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol 2014; Sep; 32 (26) 2847-2854
• Kavanagh BD, McGarry RC, Timmerman RD.. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol 2006; Apr; 16 (02) 77-84
• Andratschke N, Alheid H, Allgäuer M, Becker G, Blanck O, Boda-Heggemann J. et al The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 2018; Mar; 18 (01) 283
• Padilla GV, Presant C, Grant MM, Metter G, Lipsett J, Heide F.. Quality of life index for patients with cancer. Res Nurs Health 1983; Sep; 6 (03) 117-126 https://doi.org/10.1002/nur.4770060305